SELECT trial: difference between revisions
Diff·revision 2 → 3·21:47, 20 Aug 2024
Difference between revision 2 and revision 3 of SELECT trial. 5 lines changed; the page grew by 599 bytes.
| Revision 2 — 15:34, 9 Aug 2024 DataTableDunja (talk) add the number randomised and the number completing 1,189 bytes ±0 | Revision 3 — 21:47, 20 Aug 2024 TriumphThad (talk) give the absolute risk difference alongside the relative one 1,788 bytes +599 | ||
|---|---|---|---|
| 11 | The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).{{r|lincoff2023}} | 11 | The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).{{r|lincoff2023}} |
| 12 | 12 | ||
| + | 13 | == Design == | |
| + | 14 | Participants were 45 or older with established cardiovascular disease — prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease — and overweight or obesity, and were excluded if they had diabetes. Both groups continued standard cardiovascular care.{{r|lincoff2023}} | |
| + | 15 | ||
| + | 16 | This is an important design feature: the trial tested semaglutide added to background therapy including statins and antiplatelet agents in a majority of participants, so the observed effect is incremental to contemporary secondary prevention rather than a comparison against nothing. | |
| + | 17 | ||
| 13 | == References == | 18 | == References == |
| 14 | {{reflist}} | 19 | {{reflist}} |